BNTC · Benitec Biopharma Inc.
$8.87
+0.12 (+1.37%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$308.01M
Shares
34.88M
Volume · Oct 9
73.14K
Avg daily vol (3M)
153.61K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.87
Open$8.72
Day$8.71–9.03
52W close$8.75–16.52
Avg vol 30d168K
Short int2.0M · 5.8% float · 10.2d
Short vol66%
Last earningsSep 14, 2026
DataJan 2020–Oct 2026
Filing10-K · Sep 14
Up next
Next earnings call
Dec 30, 2026
Est · unconfirmed
· in 12 wks
filed Sep 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$45.55M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$179.97M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+27.9%
Year over year · more shares
Price change (1Y)
-37.9%
Trailing year
Short interest
5.8%
Latest settlement · 10.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−25%
below
Price vs 50-day avg
−24%
below
RSI (14)
30
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−27%
trailing
6-month return
−37%
trailing
YTD return
−34%
this year
Relative strength
−46%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $12 › 200d $12 — 200d above 50d
Institutional flow
Accumulating
2 of 86 funds reported for Sep 30 · net +306 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.85% of float · ▼ -6.7% MoM · 10.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
86 holders — near 3-yr high, broad support
Squeeze score
52
elevated · 0–100
Fundamentals
Revenue growth
−42%
Y/Y
EPS growth
+7%
Y/Y
Free cash flow
$-16.6M
Quant / Vol
risk profile
Volatility
60%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
8.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−25%
Bearish
Price vs 50-day avg
−24%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
Death cross
50d $12 › 200d $12 — 200d above 50d
Institutional flow
Accumulating
2 of 86 funds reported for Sep 30 · net +306 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.85% of float · ▼ -6.7% MoM · 10.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
86 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9
Now $9 · 2%
Range high $17
vs 200-day avg -25%
vs 50-day avg -24%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BNTC
this stock
Benitec Biopharma Inc.
|
$308.01M | -34.1% | -42.2% | — | 5.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +12.5% | +46.2% | 29.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.58B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BNTC | -1.2% | -27.2% | -36.6% | -11.3% | -34.2% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -2.4% | -29.1% | -46.5% | -13.4% | -48.3% |